human-health/
170 pages · Updated August 3, 2026
Pages
- Pardon Our Interruption
- Stroke | Boehringer Ingelheim
- Extrapulmonary Neuroendocrine Cancers | Boehringer Ingelheim
- Patient Partnership | Boehringer Ingelheim
- Cardiovascular Renal and Metabolic Health | Boehringer Ingelheim
- Lung Cancer | Boehringer Ingelheim
- Living With Cancer | Boehringer Ingelheim
- Across Cancer Types | Boehringer Ingelheim
- Patient Safety & Pharmacovigilance | Boehringer Ingelheim
- Patients – Our priority | Boehringer Ingelheim
- Liver Health | Boehringer Ingelheim
- Empowering Patients | Boehringer Ingelheim
- Chronic Kidney Disease | Boehringer Ingelheim
- Cardiovascular Health | Boehringer Ingelheim
- Hypertension | Boehringer Ingelheim
- Combivent® Respimat® | Boehringer Ingelheim
- Atrovent® | Boehringer Ingelheim
- HERNEXEOS® | Boehringer Ingelheim
- Obesity | Boehringer Ingelheim
- Giotrif® | Boehringer Ingelheim
- Glyxambi® | Boehringer Ingelheim
- Catapresan® | Boehringer Ingelheim
- Berodual® | Boehringer Ingelheim
- Berotec® | Boehringer Ingelheim
- Aptivus® | Boehringer Ingelheim
- Aggrenox® | Boehringer Ingelheim
- Alesion® | Boehringer Ingelheim
- Actilyse® | Boehringer Ingelheim
- Understanding MASH: A Global Health Challenge | Boehringer Ingelheim
- Early Detection and Chronic Kidney Disease Management | Boehringer Ingelheim
- Eye Health | Boehringer Ingelheim
- COPD & Asthma | Boehringer Ingelheim
- Scleroderma | Boehringer Ingelheim
- Neuroendocrine Cancers | Boehringer Ingelheim
- Pulmonary Fibrosis | Boehringer Ingelheim
- Bronchiectasis | Boehringer Ingelheim
- MASH | Boehringer Ingelheim
- Human Health Products | Boehringer Ingelheim
- Metabolic Health | Boehringer Ingelheim
- Human Health | Boehringer Ingelheim
- Diabetes | Boehringer Ingelheim
- Mental Health | Boehringer Ingelheim
- Heart Failure | Boehringer Ingelheim
- Lung Diseases | Boehringer Ingelheim
- Boehringer Ingelheim & Cancer Care is Personal | Boehringer Ingelheim
- Kidney Health | Boehringer Ingelheim
- European Commission approves JASCAYD novel treatment IPF PPF | Boehringer Ingelheim
- Obesity potential first-in-class triple receptor agonist Phase 2 | Boehringer Ingelheim
- Three Phase 3 trials in hard-to-treat cancers initiated | Boehringer Ingelheim
- FIBRONEER™ trials survival benefit nerandomilast IPF and PPF | Boehringer Ingelheim
- Integrated metabolic health and obesity as a policy priority | Boehringer Ingelheim
- survodutide-phase-3-fat-loss-obesity-dual-agonist-data | Boehringer Ingelheim
- China approves HERNEXEOS initial treatment lung cancer | Boehringer Ingelheim
- CHMP issues positive opinion for JASCAYD IPF and PPF in EU | Boehringer Ingelheim
- Oncology portfolio across multiple cancers ASCO 2026 | Boehringer Ingelheim
- Obesity: breaking stigma and driving change | Boehringer Ingelheim
- JASCAYD approved in Japan new IPF and PPF treatment | Boehringer Ingelheim
- glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement | Boehringer Ingelheim
- Building a network of support for neuroendocrine cancer communities: Susan’s story | Boehringer Ingelheim
- The challenges of facing neuroendocrine cancer: Jim’s story | Boehringer Ingelheim
- Study results zongertinib HER2-mutant advanced NSCLC published NEJM | Boehringer Ingelheim
- Idiopathic Pulmonary Fibrosis (IPF): Ron and Maxine’s Story | Boehringer Ingelheim
- High-grade neuroendocrine carcinoma: biology, unmet needs, and DLL3 biomarker in epNEC & SCLC | Boehringer Ingelheim
- Why we lift up the patient voice: When patients speak, systems change | Boehringer Ingelheim
- Why biomarker testing matters in cancer care | Boehringer Ingelheim
- FDA approves HERNEXEOS first line lung cancer | Boehringer Ingelheim
- Driving mental health reform through collective action | Boehringer Ingelheim
- Empowering Patients to Advocate with Patient Experience Data (PED) | Boehringer Ingelheim
- Boehringer received FDA Commissioner’s National Priority Voucher | Boehringer Ingelheim
- Extrapulmonary neuroendocrine carcinomas (epNEC): a rare and aggressive cancer explained | Boehringer Ingelheim
- The impact of biomarker testing in stage 4 lung cancer | Boehringer Ingelheim
- Boehringer announces Phase 2 results in FSGS rare kidney disease | Boehringer Ingelheim
- Electronic product information: Is this the end of the paper leaflets? | Boehringer Ingelheim
- Understanding biomarker testing in lung cancer | Boehringer Ingelheim
- Zongertinib 77 percent response rate advanced HER2 mutant NSCLC | Boehringer Ingelheim
- Beats of Change: Lynn’s story with CVD and CKD | Boehringer Ingelheim
- Holistic CRM care: Saving lives by breaking silos | Boehringer Ingelheim
- What´s new in pulmonary fibrosis? | Boehringer Ingelheim
- Addressing multimorbidity: A call for integrated care to tackle NCDs | Boehringer Ingelheim
- Boehringer Ingelheim gets approval for HERNEXEOS® in Japan | Boehringer Ingelheim
- HERNEXEOS shows intracranial responses in HER2 NSCLC patients | Boehringer Ingelheim
- HERNEXEOS® approved China targeted therapy NSCLC | Boehringer Ingelheim
- NSCLC and brain metastasis: understanding the hidden journey from lungs to brain | Boehringer Ingelheim
- Small Cell Lung Cancer | Boehringer Ingelheim
- Boehringer LEO Pharma partnership commercialize SPEVIGO | Boehringer Ingelheim
- Fostering the mental health community in the Americas | Boehringer Ingelheim
- Schizophrenia in real life: Fighting broken care pathways | Boehringer Ingelheim
- Phase III AIRTIVITY trial | Boehringer Ingelheim
- CRM integrated care World Health Assembly | Boehringer Ingelheim
- Global Patient Partnership Summit (GPPS) Connections | Boehringer Ingelheim
- One Billion Lives: Why Integrated Care Can’t Wait | Boehringer Ingelheim
- Our Path Forward | Boehringer Ingelheim
- New indication and extension OFEV® children adolescents | Boehringer Ingelheim
- Addressing the Global Obesity and Liver Crisis | Boehringer Ingelheim
- One day, two lives: how a stroke changed Horst’s life | Boehringer Ingelheim
- About Chronic Kidney Disease | Boehringer Ingelheim
- CHMP recommends approval of OFEV® in children adolescents ILDs | Boehringer Ingelheim
- Global Patient Partnership Initiative (GPPI) | Boehringer Ingelheim
- Global Patient Partnership Initiative (GPPI) | Boehringer Ingelheim
- Joint efforts to address the global CRM health crisis | Boehringer Ingelheim
- Breathing hope: fighting the lung disease pulmonary fibrosis | Boehringer Ingelheim
- Expert insights: the top online lung cancer questions answered | Boehringer Ingelheim
- Partnership WHO Foundation mental health | Boehringer Ingelheim
- EASi-KIDNEY™ Phase III trial for people with CKD | Boehringer Ingelheim
- Survodutide US FDA Breakthrough Therapy phase 3 trials MASH | Boehringer Ingelheim
- Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met | Boehringer Ingelheim
- Schizophrenia in real life | Boehringer Ingelheim
- Patient-Powered Progress | Boehringer Ingelheim
- Are you missing the bigger picture on mental health? | Boehringer Ingelheim
- EASi-HF™ Phase III trial in patients with HFpEF | Boehringer Ingelheim
- Big Little Things in cancer: small things, big impacts | Boehringer Ingelheim
- Larry’s Story: Advocating for people with lung cancer | Boehringer Ingelheim
- Sharing knowledge from our medical device development | Boehringer Ingelheim
- Rethinking mental health care | Boehringer Ingelheim
- Non-Small Cell Lung Cancer (NSCLC) | Boehringer Ingelheim
- Breaking prejudice in lung cancer | Boehringer Ingelheim
- Results for Jardiance EMPACT-MI phase III trial | Boehringer Ingelheim
- The liver and its vital connection to our overall health | Boehringer Ingelheim
- survodutide top-line results MASH fibrosis | Boehringer Ingelheim
- Our mission in cardiovascular, renal, and metabolic care | Boehringer Ingelheim
- The power of patient advocacy in cancer care | Boehringer Ingelheim
- Transforming Cancer Care | Boehringer Ingelheim
- Experiences of living with cancer | Boehringer Ingelheim
- Promising phase II results in chronic kidney disease | Boehringer Ingelheim
- Digital solution for individualized diabetes care | Boehringer Ingelheim
- Phase 3 studies survodutide obesity and overweight | Boehringer Ingelheim
- FDA approves Jardiance treatment chronic kidney disease | Boehringer Ingelheim
- Living with pulmonary fibrosis and finding hope | Boehringer Ingelheim
- Survodutide Phase III study weight loss | Boehringer Ingelheim
- Dedifferentiated liposarcoma: Life with an ultra rare cancer | Boehringer Ingelheim
- Phase II trials for patients with bronchiectasis | Boehringer Ingelheim
- CHMP recommends new treatment for chronic kidney disease | Boehringer Ingelheim
- Phase II clinical trial weight loss results | Boehringer Ingelheim
- Interstitial lung disease in rheumatoid arthritis (RA-ILD) | Boehringer Ingelheim
- FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs | Boehringer Ingelheim
- Cancer is One of Humanity’s Greatest Challenges | Boehringer Ingelheim
- FDA accepts new chronic kidney disease treatment application | Boehringer Ingelheim
- Full data chronic kidney disease trial efficacy | Boehringer Ingelheim
- New data for nintedanib in children with fibrosing ILD | Boehringer Ingelheim
- Facing pulmonary fibrosis | Boehringer Ingelheim
- Facing lung cancer | Boehringer Ingelheim
- Living with type 2 diabetes | Boehringer Ingelheim
- EMPA-KIDNEY trial early stop due to positive efficacy | Boehringer Ingelheim
- FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF | Boehringer Ingelheim
- Nurjanahs Story | Boehringer Ingelheim
- FDA- HFpEF-breakthrough-designation-EMPEROR-preserved | Boehringer Ingelheim
- 100-year anniversary of BI in respiratory care | Boehringer Ingelheim
- Stargardt Disease | Boehringer Ingelheim
- Diabetic macular edema and diabetic macular ischemia | Boehringer Ingelheim
- Diabetic Retinopathy | Boehringer Ingelheim
- A clear vision | Boehringer Ingelheim
- Podcast: Journeys through pulmonary fibrosis | Boehringer Ingelheim
- InPedILD_trial_enrollment | Boehringer Ingelheim
- European_Commission_approves_nintedanibSSc-ILD | Boehringer Ingelheim
- FDA-Fast-Track-chronic-kidney-disease | Boehringer Ingelheim
- Scleroderma Life Hacks | Boehringer Ingelheim
- EURORDIS Award | Boehringer Ingelheim
- Finding the right inhaler for you | Boehringer Ingelheim
- Major investment for respiratory diseases completed | Boehringer Ingelheim
- A Unique Bond: by my side | Boehringer Ingelheim
- A Unique Bond: a brotherhood like no other | Boehringer Ingelheim
- The little things | Boehringer Ingelheim
- More Than Scleroderma | Boehringer Ingelheim
- The FAST Test | Boehringer Ingelheim
- Systemic sclerosis physician video | Boehringer Ingelheim
- Facts About IPF | Boehringer Ingelheim
- Hayley – My Life With Asthma | Boehringer Ingelheim
- Katherine – My Asthma And Me | Boehringer Ingelheim
- Facts About Asthma | Boehringer Ingelheim
- IPF Video Infographic | Boehringer Ingelheim